PT-141 (Bremelanotide): the complete research guide.

PT-141, or bremelanotide, is a synthetic 7-amino-acid peptide that acts on melanocortin receptors in the brain. It's FDA-approved as Vyleesi for low sexual desire in premenopausal women, and nothing else. Most research use you'll see is off-label in men, where the Phase III program was discontinued. We map what the evidence actually supports.

Bremelanotide started as a metabolite of melanotan II. Melanotan II was a tanning peptide developed in the 1980s. Some users reported an unexpected side effect: spontaneous erections and changes in sexual desire. Palatin Technologies took the metabolite, the cyclic 7-amino-acid peptide we now call PT-141, and built it into a deliberate sexual-desire drug.

The FDA approved it in June 2019 for premenopausal women with acquired, generalized HSDD. Five years on, Vyleesi remains a niche product commercially. But PT-141 has become one of the most actively traded research peptides in the grey market. Almost all of that use is off-label in men.

That gap between the approved use and the observed use is the structural problem here. The Phase III evidence sits in premenopausal women with HSDD. The documented off-label use is mostly in men, looking at erectile or desire endpoints. Our read is that the evidence doesn't transfer cleanly.

The side effects don't care about the label. Nausea, brief blood-pressure spikes and skin darkening at frequent dosing all become more relevant, not less, the further use drifts from what was tested.

What does bremelanotide actually do?

Bremelanotide is a synthetic cyclic 7-amino-acid peptide. It binds the melanocortin family of brain targets, MC1R through MC5R, without preference. The therapeutic effect on sexual desire is mostly attributed to MC4R activation in the medial preoptic area of the hypothalamus. That's a small brain region near the middle. It's the best-mapped center for sexual motivation.

The neurobiology review by Pfaus and colleagues describes the cascade in 3 steps. The peptide activates MC4R neurons in the medial preoptic area. Those neurons increase dopamine release downstream. That dopamine drives the subjective experience of desire and arousal.

This is fundamentally different from how Viagra-style drugs work. Sildenafil and tadalafil act on smooth muscle in the penis to help an erection when arousal already exists. Bremelanotide acts in the brain on the regions that create desire in the first place.

That distinction carries real clinical weight. If desire is intact and the problem is vascular, PDE5 inhibitors are the class that fits. The HSDD population is defined by lost motivation or interest, and that's the population bremelanotide was built for.

The two drug classes hit different stages of the same response pathway. They aren't two routes to one target.

Bremelanotide isn't selective for MC4R alone. That's where the main side effects come from. MC1R activation on skin pigment cells causes darkening, which is the original reason melanotan II was a tanning compound. That same activity explains the focal skin darkening you see with frequent dosing.

MC3R activation in the hypothalamus has metabolic and appetite-blunting effects. The 40% nausea rate in the Phase III trials traces back to combined MC3R/MC4R activation in brainstem regions that share circuits with the body's vomiting reflex center.

PT-141 (Bremelanotide)

Cyclic heptapeptide 7 aa Melanocortin agonist

The same compound cited across the Phase III RECONNECT trials and the cited safety analyses. Lab-verified identity and purity.

Shop PT-141

What did the RECONNECT Phase III trials actually show?

FDA approval rests on two 24-week double-blind placebo-controlled trials. RECONNECT-1 enrolled 1,247 women. RECONNECT-2 enrolled 1,202. All had diagnosed acquired, generalized HSDD. Subjects self-injected 1.75 mg of bremelanotide or placebo about 45 minutes before sex, capped at one dose per 24 hours and eight doses per month.

Primary outcomes were two patient-reported measures: the Female Sexual Function Index desire score, and Item 13 of the Female Sexual Distress Scale. Simon and colleagues reported statistically significant improvements on bremelanotide versus placebo across age, weight, BMI, hormonal contraception, and testosterone subgroups. The headline efficacy finding is statistically supported.

What the principal publications didn't foreground is what Spielmans's re-analyses surfaced. He compared the published outcomes against the pre-specified protocol on ClinicalTrials.gov. We think that comparison is the single most useful thing anyone has done with this dataset.

That participant-preference signal is the most uncomfortable finding for the marketing story. A drug people clearly prefer should pull more of its own arm into the open-label extension than the placebo arm. We see the reverse pattern here.

Spielmans and Ellefson's 2024 follow-up analyzed 11 protocol-specified efficacy outcomes. Eight had never been published. They concluded effect sizes ran "from nil to small," and questioned whether the primary outcome measures captured what they claimed to.

None of this invalidates the FDA approval. The agency saw the full data package, accepted the pre-specified primary endpoints, and approved on that basis.

It does change how you should read the efficacy evidence. Bremelanotide produced a real, statistically significant, modest improvement on patient-reported desire and distress scales. We think the pre-marketing story overstated that against what the full dataset showed.

What is the side-effect profile?

The pooled Phase 1–3 safety dataset by Clayton and colleagues covered 3,500 subjects across 43 studies, plus an 18-month open-label extension. The dominant signal is nausea.

• Nausea: 40.0% vs 1.3% placebo. The most common adverse event and the top reason study participants discontinued. Onset was rapid (within an hour of injection in trial protocols). Most cases were mild to moderate, but a meaningful proportion were sufficient to make continued participation aversive.
• Flushing: 20.3% vs 1.3%. Transient. Peaked alongside the nausea window. Generally resolved within 2–4 hours.
• Headache: 11.3% vs 1.9%. Mild-to-moderate in the trial population.
• Injection-site reactions: 5.4% vs 0.5%. Tolerability of the autoinjector was generally acceptable in the trial population.
• Brief blood-pressure spike. Ambulatory monitoring documented small but real increases. The approved label warns against use with uncontrolled high blood pressure or known heart disease.
• Skin darkening (focal hyperpigmentation). Rare at label-recommended dosing frequency (8 doses/month cap in the approved indication). Over a third of research subjects given 16 consecutive daily doses in a sub-study developed pigmentation changes.

That hyperpigmentation signal from the extended-dosing sub-study is the finding most relevant to grey-market use. The 8-doses-per-month cap belongs to the approved indication. The 16-consecutive-daily-doses subgroup sits in a different research context, and the main Phase III program never validated it.

What about off-label use in men?

PT-141 in men is the question most buyers actually want answered, and we'll give you the uncomfortable version. Palatin discontinued the bremelanotide program in men. Phase III evidence for male sexual dysfunction is far thinner than the female HSDD data. The trials that ran didn't build the regulatory case Palatin needed, and no FDA-approved label for male use exists.

Off-label male use rests on three lines of reasoning:

• Mechanism isn't sex-specific. The hypothalamic brain circuit the drug targets exists in both sexes.
• Anecdotal and case-series reports describe desire-related and erectile effects in men that look qualitatively similar to what the female HSDD trials reported.
• The regulatory absence in men reflects commercial strategy and trial design more than a clean negative efficacy signal.

None of those three lines equals randomized trial evidence. Off-label male use extrapolates from a contested female-HSDD dataset to an indication the drug was tested for and failed to win approval in. In our reading, the nausea, the transient blood-pressure spike and the skin-darkening risk carry over to any use of the compound.

PT-141 (Bremelanotide)

10 mg ≥99% pure Lyophilized

Cyclic heptapeptide · non-selective MCR agonist. The same reference compound used across the cited Phase III studies. COA available with each lot.

Learn more

Does bremelanotide interact with other drugs?

The Phase III safety analyses found two clinically meaningful drug interactions. Bremelanotide reduces blood levels of indomethacin, an anti-inflammatory, and naltrexone, which blocks opioids. Both reductions make sense mechanically. Bremelanotide slows stomach emptying through MC4R brain effects, which delays the absorption of oral drugs.

The clinical significance varies. Indomethacin's anti-inflammatory effect may drop. Naltrexone's opioid blockade may partly lift. That last one matters for people using naltrexone for alcohol or opioid use disorder.

The label also flags caution with blood-pressure drugs, given the brief BP spike. And caution with alcohol, though that isn't formally a metabolic interaction. The drug's brain dopamine effects make interactions with dopamine-blocking drugs plausible in theory. That covers antipsychotics and many anti-nausea meds. Nobody has studied it formally.

What is the regulatory status outside the US?

Bremelanotide is FDA-approved in the United States only. The European Medicines Agency has not approved Vyleesi. Palatin chose not to pursue EMA approval rather than risk a negative determination.

WADA has not named bremelanotide on the Prohibited List. Peptides in the wider melanocortin family sometimes get evaluated under S0, the non-approved-substances category, so check status with the relevant governing body yourself. No major professional league explicitly prohibits it as of this review.

Clinical context and research gaps

Inside the approved indication, bremelanotide is one of two FDA-approved drugs for premenopausal women with acquired, generalized HSDD. The other is flibanserin, sold as Addyi, a daily oral agent with a different mechanism and its own tolerability problems.

The Phase III dataset is real and the side-effect profile is documented. So is the patient-preference signal from the open-label extension, which literature reviews keep coming back to.

For off-label use in men, the literature points to five evidence gaps that researchers and clinicians keep flagging.

• Standard-of-care context. Published clinical guidance for male sexual dysfunction identifies vascular, hormonal, and psychological factors as the predominant contributors, with established evidence-based interventions. Central desire-pathway dysfunction as a primary etiology is rarely the first clinical consideration in male populations.
• Methodological critiques. The Spielmans re-analyses (2021, 2024) are the most comprehensive independent assessments of the RECONNECT dataset and their conclusions differ substantially from the sponsor-funded publications — a distinction relevant to any evidence evaluation.
• Cardiovascular safety signals. The transient blood-pressure elevation documented in the Phase III safety dataset and flagged in the label is not limited to the approved indication by mechanism; it is an on-target pharmacological effect.
• Extended-dosing hyperpigmentation data. The sub-study reporting skin-darkening rates above the approved dosing frequency represents the primary available safety signal for higher-frequency use patterns, regardless of indication.
• Purity and identity verification. Multiple analytical studies (Mestria et al., 2021) have documented bremelanotide and melanotan II in adulterated grey-market products of uncertain purity and identity — a compound-integrity issue independent of the pharmacological evidence.

What is the rest of the melanocortin family doing in oncology?

An emerging strand of bremelanotide research has nothing to do with sexual medicine. Suzuki and colleagues at a Japanese oncology group showed in 2024 that bremelanotide reduces survivin, a cancer-survival protein, in glioblastoma cell lines via MC3R/MC4R signaling. It triggered cancer cell death and made cells more sensitive to temozolomide and osimertinib without harming normal cells.

We'd call that drug repurposing in test tubes, not a clinical recommendation. It's still a reminder that the brain circuits bremelanotide engages reach further than the sexual-desire approval suggests.

The polymorphism review by Bardhan and colleagues surveys melanocortin variants in inflammatory traits and chronic diseases. Sweeney and colleagues' 2023 review in Nature Reviews Endocrinology calls the brain melanocortin system one of the most promising targets for metabolic drugs.

That case got stronger when setmelanotide, a related MC4R-targeting peptide, won FDA approval for rare genetic obesity. Bremelanotide sits in the same family, with different selectivity and a different commercial path.